Compare MSS & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSS | VBIO |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 1.1M |
| IPO Year | 2023 | 2021 |
| Metric | MSS | VBIO |
|---|---|---|
| Price | $1.24 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 123.7K | ★ 658.1K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,217,480.00 | $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.01 | N/A |
| 52 Week Low | $0.42 | $0.12 |
| 52 Week High | $775.50 | $812.50 |
| Indicator | MSS | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 22.30 |
| Support Level | $1.10 | $0.12 |
| Resistance Level | $1.82 | $4.39 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.02 | 1.97 |
| Stochastic Oscillator | 13.76 | 1.29 |
Maison Solutions Inc is a fast-growing, specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly members of Asian-American communities. It is committed to providing Asian fresh produce, meat, seafood, and other daily necessities in a manner that caters to traditional Asian-American family values and cultural norms, while also accounting for the new and faster-paced lifestyle of younger generations and the diverse communities in which it operates. The company's merchandise includes fresh and, meats, seafood, and other groceries that are not found in mainstream supermarkets, including a variety of Asian vegetables and fruits such as broccoli, bitter melon, winter gourd, Shanghai baby bok choy, longan, and lychee.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.